Research programme: anti-interleukin monoclonal antibodies - GiulianiAlternative Names: GED 0408
Latest Information Update: 16 Jul 2016
At a glance
- Originator Giuliani
- Developer Nogra Pharma
- Class Monoclonal antibodies
- Mechanism of Action Interleukin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Italy
- 30 Apr 2008 Early research in Undefined indication in Italy (unspecified route)